Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.52M
Average 0.39M
SION Total Current Liabilities
All obligations due within one year.
Sionna Therapeutics, Inc.NASDAQ: SION
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 2.6% from a year ago
Total current liabilities stood at $9.78M at the end of Q1 FY2026, up 2.6% from a year earlier and down 16.5% from the prior quarter. Over 3 fiscal years it compounded at +12.4% a year.
Context
- Total current liabilities amounted to 3.2% of total assets at the end of Q1 FY2026, up 0.6 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +2.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 11.71M USD
- Year-over-year change
- +12.4%
- 3-year CAGR
- +12.4%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.71M | +12.4% |
| FY2024 | 2024-12-31 | 10.42M | +29.7% |
| FY2023 | 2023-12-31 | 8.04M | -2.6% |
| FY2022 | 2022-12-31 | 8.25M | — |
Total Current Liabilities vs competitors
How SION compares with its peers on the latest reported figures
- SION's Mar 2026 total current liabilities of $9.78M is the lowest of the 11 companies compared; the peer median is $61.59M.
- Its year-over-year change of +2.6% is the 9th highest of 11, against a peer median of +30.3%.
- Total current liabilities amounts to 3.2% of total assets for SION, versus a peer median of 8.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $161.46M | +284.0% | -23.8% | 13.7% | |
| Mar 2026 | $118.59M | +24.7% | +14.2% | 30.3% | |
| Mar 2026 | $109.57M | +44.5% | +10.5% | 21.7% | |
| Sep 2026 | $70.47M | +2.4% | -18.4% | 4.7% | |
| Jun 2026 | $62.66M | -49.6% | +8.8% | 16.9% | |
| Sep 2026 | $60.52M | +30.2% | +39.9% | 8.4% | |
| Mar 2026 | $58.92M | +236.6% | +14.8% | 5.7% | |
| Jun 2026 | $48.32M | +44.0% | +27.8% | 9.1% | |
| Sep 2026 | $40.97M | +30.3% | +83.1% | 8.1% | |
| Mar 2026 | $21.24M | +14.1% | +2.8% | 5.1% | |
| Mar 2026 | $9.78M | +2.6% | +12.4% | 3.2% | |
| Peer median (excluding SION) | $61.59M | +30.3% | +12.4% | 8.7% | |
Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Sionna Therapeutics, Inc.
NASDAQ:SION
Intrinsic Alpha fair value
Locked
Current Price
$2.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.